Contrast injector technology firm Medrad of Warrendale, PA, has received 510(k) clearance from the U.S. Food and Drug Administration for Intego, a PET radiopharmaceutical infusion system.
Intego automates many of the steps involved in the infusion of FDG for PET studies. The system automatically extracts a patient dose from a multidose vial and delivers it to the patient, eliminating most steps in manual dose preparation and handling, as well as reducing radiation exposure to technologists, according to Medrad.
Safety features include a tungsten multidose vial shield, a lead-lined mobile cart, and an automated saline flush to remove residual FDG from the line after each infusion.
Related Reading
Medrad, PETNet partner for FDG, June 13, 2008
Medrad to offer blood analyzer, April 10, 2008
Medrad completes Possis tender offer, March 27, 2008
Medrad revenues climb in 2007, March 4, 2008
Covidien settles Medrad litigation, February 14, 2008
Copyright © 2008 AuntMinnie.com
